<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00319670</url>
  </required_header>
  <id_info>
    <org_study_id>851-201</org_study_id>
    <nct_id>NCT00319670</nct_id>
  </id_info>
  <brief_title>A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children</brief_title>
  <official_title>A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <brief_summary>
    <textblock>
      To evaluate patient acceptance of a new MiraLax dose formulation in children currently&#xD;
      treated with polyethylene glycol 3350 powder for treatment of constipation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate patient acceptance of a new MiraLax dose formulation in children currently&#xD;
      treated with polyethylene glycol 3350 powder for treatment of constipation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy will be measured by analysis of patient self-reported BM data.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events will be monitored and analyzed for safety purposes.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient acceptance will be measured by analysis of subjective questionnaire data.</measure>
  </secondary_outcome>
  <enrollment>25</enrollment>
  <condition>Constipation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MiraLax</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female constipated outpatients between the ages of 4 and 16&#xD;
&#xD;
          2. Currently taking a dose of less than or equal to 17g of PEG 3350 powder that has been&#xD;
             consistent for at least 4 weeks&#xD;
&#xD;
          3. Current treatment is considered successful - defined as greater than 2 bowel movements&#xD;
             per week with no accidents&#xD;
&#xD;
          4. Are otherwise in good health, as judged by a physical examination&#xD;
&#xD;
          5. If female and of childbearing potential, patient must be using oral contraceptives,&#xD;
             depot contraceptives, intrauterine device, or testifies that she is monogamous with a&#xD;
             vasectomized partner, or practices abstinence and will continue to do so during the&#xD;
             duration of study&#xD;
&#xD;
          6. In the investigator's judgment, patient or guardian is mentally competent to sign an&#xD;
             instrument of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with heme positive stool at baseline exam&#xD;
&#xD;
          2. Patients who are impacted at baseline exam&#xD;
&#xD;
          3. Patients that are not receiving PEG 3350&#xD;
&#xD;
          4. Patients on PEG 3350 that continue to have problems&#xD;
&#xD;
          5. Patients with known or suspected perforation or obstruction&#xD;
&#xD;
          6. Patients with a history of gastric retention, inflammatory bowel disease, bowel&#xD;
             resection, or colostomy&#xD;
&#xD;
          7. Patients with a known history of organic cause for their constipation.&#xD;
&#xD;
          8. Patients currently using medications known to cause constipation. These include&#xD;
             Opiates, antidepressants, SSRI's, antimotility agents and anticholinergics.&#xD;
&#xD;
          9. Patients who are breastfeeding, pregnant, or intend to become pregnant during the&#xD;
             study&#xD;
&#xD;
         10. Female patients of childbearing potential who refuse a pregnancy test&#xD;
&#xD;
         11. Patients who, in the opinion of the investigator, should not be included in the study&#xD;
             for any reason, including inability to follow study procedure&#xD;
&#xD;
         12. Patients with known allergy to PEG or PEG containing medications&#xD;
&#xD;
         13. Patients who, within the past 30 days have participated in an investigational clinical&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Nurko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>April 27, 2006</study_first_submitted>
  <study_first_submitted_qc>April 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <keyword>constipation</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyethylene glycol 3350</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

